Maraj Ilir, Gonzalez Mario D, Naccarelli Gerald V
Cardiology Division/EP Section, Department of Medicine, Heart and Vascular Institute, Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA.
J Innov Card Rhythm Manag. 2018 Aug 15;9(8):3274-3281. doi: 10.19102/icrm.2018.090801. eCollection 2018 Aug.
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice today. For those who present with it, one of the most major risks associated with the condition is stroke. AF is associated with a fivefold increased risk of stroke and thromboembolism. Oral anticoagulation has been the cornerstone of stroke prevention in patients with AF. In some individuals who exhibit a higher risk of bleeding, other alternatives for stroke prevention have been sought, including the use of left atrial appendage occlusion devices and surgical exclusion of the left atrial appendage. Catheter ablation is an important treatment strategy in those patients for whom a rhythm control strategy has been selected. This article reviews some of the available anticoagulant drug options and their use prior to, during, and after catheter ablation.
心房颤动（AF）是当今临床实践中最常见的持续性心律失常。对于患有心房颤动的患者而言，与该病症相关的最主要风险之一是中风。心房颤动与中风和血栓栓塞风险增加五倍相关。口服抗凝治疗一直是心房颤动患者预防中风的基石。在一些出血风险较高的个体中，人们一直在寻找其他预防中风的替代方法，包括使用左心耳封堵装置和手术切除左心耳。对于选择节律控制策略的患者，导管消融是一种重要的治疗策略。本文回顾了一些可用的抗凝药物选择及其在导管消融术前、术中和术后的使用情况。
